Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Metastatic Castration-Resistant Prostate Cancer
Sort By
Newest First
Sign in
1 / 1
1 / 1
Cu-67 SAR-bisPSMA
Clarity Receives US FDA Fast Track Designation for Treating Metastatic Castration-Resistant Prostate Cancer with Cu-67 SAR-bisPSMA
Clarity Pharmaceuticals
PR-02-25-NI-19
Feb 19, 2025
Clinical Trials
Harpoon Therapeutics Treats First Patient with HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
Harpoon Therapeutics
PR-M08-18-NI-051
Aug 13, 2018
